SC
SPRO icon

Shay Capital’s Spero Therapeutics SPRO Stock Holding History

Shay Capital’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$165K Buy
70,354
+10,065
+17% +$23.9K 0.01% 404
2025
Q4 		$140K Sell
60,289
-3,378
-5% -$7.84K 0.01% 436
2025
Q3 		$120K Buy
+63,667
New +$140K 0.01% 374
2024
Q4 		– Sell
-25,000
Closed -$33.5K – 423
2024
Q3 		$33.5K Hold
25,000
– – ﹤0.01% 299
2024
Q2 		$32.5K Sell
25,000
-281,967
-92% -$425K ﹤0.01% 251
2024
Q1 		$528K Buy
+306,967
New +$481K 0.08% 173

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Shay Capital's SPRO Position: Q1 2026 in Review

Shay Capital increased its Spero Therapeutics (SPRO) stake by 17% in Q1 2026, buying an estimated $23.9K and bringing the position to 70,354 shares worth $165K. The position accounts for 0.01% of the portfolio, ranked #404.

Shay Capital first reported a position in SPRO in Q1 2024 and has held it in 6 quarters since. The position peaked at $528K in Q1 2024. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Shay Capital held 70,354 shares of Spero Therapeutics worth $165K as of Q1 2026.
  • Shay Capital bought 10,065 Spero Therapeutics shares in Q1 2026, an estimated $23.9K.
  • Spero Therapeutics made up 0.01% of Shay Capital's portfolio in Q1 2026, its #404 holding.
  • Shay Capital first reported a position in Spero Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • Shay Capital's Spero Therapeutics position peaked at $528K in Q1 2024.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Shay Capital's 13F filing for Q1 2026, filed 15 May 2026.